State of Wisconsin Investment Board lowered its position in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 63.7% during the first quarter, according to its most recent filing with the SEC. The fund owned 3,307 shares of the biopharmaceutical company’s stock after selling 5,811 shares during the period. State of Wisconsin Investment Board’s holdings in Intercept Pharmaceuticals were worth $374,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. State Board of Administration of Florida Retirement System boosted its stake in shares of Intercept Pharmaceuticals by 2.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 23,736 shares of the biopharmaceutical company’s stock valued at $2,579,000 after buying an additional 589 shares during the period. State Street Corp boosted its stake in shares of Intercept Pharmaceuticals by 20.2% in the fourth quarter. State Street Corp now owns 751,027 shares of the biopharmaceutical company’s stock valued at $81,600,000 after buying an additional 126,011 shares during the period. FMR LLC boosted its stake in shares of Intercept Pharmaceuticals by 0.3% in the fourth quarter. FMR LLC now owns 3,721,316 shares of the biopharmaceutical company’s stock valued at $404,321,000 after buying an additional 12,360 shares during the period. Marshall Wace LLP boosted its stake in shares of Intercept Pharmaceuticals by 180.7% in the fourth quarter. Marshall Wace LLP now owns 102,360 shares of the biopharmaceutical company’s stock valued at $11,121,000 after buying an additional 65,892 shares during the period. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at about $706,000. 84.35% of the stock is currently owned by institutional investors and hedge funds.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) opened at 118.40 on Monday. Intercept Pharmaceuticals, Inc. has a 52 week low of $96.63 and a 52 week high of $177.93. The company’s market capitalization is $2.96 billion. The firm’s 50-day moving average price is $116.20 and its 200 day moving average price is $113.79.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million during the quarter, compared to the consensus estimate of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. Intercept Pharmaceuticals’s quarterly revenue was up 4566.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($5.17) EPS. Equities analysts predict that Intercept Pharmaceuticals, Inc. will post ($14.50) EPS for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/intercept-pharmaceuticals-inc-icpt-position-cut-by-state-of-wisconsin-investment-board/1039967.html.
Several equities research analysts have recently issued reports on the company. Citigroup Inc. set a $240.00 target price on Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 28th. Cowen and Company reaffirmed a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 8th. BMO Capital Markets lifted their target price on Intercept Pharmaceuticals from $198.00 to $221.00 and gave the stock an “outperform” rating in a report on Friday, February 24th. Finally, Credit Suisse Group lifted their target price on Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a report on Friday, May 5th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $190.98.
In other Intercept Pharmaceuticals news, insider Lisa Bright sold 254 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $117.52, for a total value of $29,850.08. Following the completion of the sale, the insider now owns 23,246 shares in the company, valued at approximately $2,731,869.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CMO David Shapiro sold 1,117 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the completion of the sale, the chief marketing officer now owns 46,582 shares of the company’s stock, valued at approximately $5,225,568.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,016 shares of company stock valued at $452,624. 4.50% of the stock is owned by insiders.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.